Literature DB >> 15317885

Viral entry denied.

Robert W Doms1.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15317885     DOI： 10.1056/NEJMp048058

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.

Authors:  Cécile L Tremblay; Françoise Giguel; Yongbiao Guan; Ting-Chao Chou; Katsunori Takashima; Martin S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 2.  Lectins Are the Sparkle of Hope for Combating Coronaviruses and the Global COVID-19.

Authors:  Heba Salah Abbas; Muddukrishnaiah Kotakonda
Journal:  Adv Pharm Bull       Date:  2021-03-27

Review 3.  Development of novel entry inhibitors targeting emerging viruses.

Authors:  Yanchen Zhou; Graham Simmons
Journal:  Expert Rev Anti Infect Ther       Date:  2012-10       Impact factor: 5.091

4.  X4 Human immunodeficiency virus type 1 gp120 promotes human hepatic stellate cell activation and collagen I expression through interactions with CXCR4.

Authors:  Feng Hong; Yedidya Saiman; Chuanping Si; Arevik Mosoian; Meena B Bansal
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

5.  Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle.

Authors:  Els Keyaerts; Leen Vijgen; Christophe Pannecouque; Els Van Damme; Willy Peumans; Herman Egberink; Jan Balzarini; Marc Van Ranst
Journal:  Antiviral Res       Date:  2007-03-30       Impact factor: 5.970
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.